Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102882 · ClinicalTrials.gov registry record · Phase 4
Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 547
- Enrollment target
NCT00102882 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 547 participants.
The verdict
NCT00102882, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 547 participants
- Enrollment target
Study Summary
This study may last up to 36-38 weeks. Patients will visit the clinic 11 times. A blood sample will be taken at Visit 1 to look at subjects' genes. Breathing tests will be done during the study. Study medicines and procedures will be provided at no cost. Patients will be treated with VENTOLIN (8 wks), ATROVENT (8 wks), then ADVAIR or SEREVENT (16 wks). ADVAIR and SEREVENT are FDA approved for the treatment of asthma in patients 4 years of age and older.
Interventions
- DRUG fluticasone propionate/salmeterol
- DRUG salmeterol xinafoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 547 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102882
The ClinicalTrials.gov registry entry for NCT00102882 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 547 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fluticasone propionate/salmeterol is the first listed.
NCT00102882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102882 about?
NCT00102882 is a clinical study titled "Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate". This study may last up to 36-38 weeks. Patients will visit the clinic 11 times. A blood sample will be taken at Visit 1 to look at subjects' genes. Breathing tests will be done during the study. Study medicines and procedures will be provided at no cost. Patients will be treated with VENTOLIN (8 wks...
What is the current status of trial NCT00102882?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 547 participants. The study started on 2004-10. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00102882?
The interventions under investigation include: fluticasone propionate/salmeterol (DRUG), salmeterol xinafoate (DRUG).
Who is sponsoring clinical trial NCT00102882?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.